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Exercise capacity in hypertrophic cardiomyopathy is 
thought to relate to elevated left atrial pressure as a 
consequence of impaired diastolic function, but this as- 
sumption has not previously been evaluated. Twenty-three 
patients with hypertrophic cardiomyopathy underwent be- 
modynamic assessment during symptom-limited maximal 
exercise with objective measurement of exercise capacity by 
respiratory gas analysis. Maximal oxygen consumption and 
anaerobic threshold were 28.1 * 7.5 and 21.5 f 6.1 ml/kg 
per min, respectively (the lower limit of reference range in 
our laboratory is 39 and 27 ml/kg per min, respectively). 
Maximal oxygen consumption was reduced in 11 of 13 
patients who were in New York Heart Association func- 
tional class I and who denied limitation of exercise capacity 
and in all 10 patients who were in functional class II or HI. 
Maximal oxygen consumption and anaerobic threshold 
were related to peak cardiac index (r = 0.650, p < 0.001 
and r = 0.459, p = 0.03, respectively) and to the increase 
in cardiac index on exercise (r = 0.677, p < 0.001 and r = 
0.509, p = 0.016, respectively), but not to cardiac index at 
rest, peak and rest pulmonary capillary wedge pressure, 
pulmonary capillary wedge pressure at an oxygen con- 
sumption of 15 ml/kg per min or the rise in pulmonary 
capillary wedge pressure on exercise. These findings are not 
consistent with the hypothesis that elevated left atrial 
pressure is the major determinant of exercise capacity in 
patients with hypertrophic cardiomyopathy and they sug- 
gest that, as in patients with chronic cardiac failure, other 
mechanisms should be considered. 
(J Am Co11 Cardiol1989;13:1521-6) 
In hypertrophic cardiomyopathy, dyspnea is common (l-3). 
diastolic function often impaired (4,.5) and left atria1 pressure 
elevated (6). Dyspnea has been considered to be a conse- 
quence of a rapid increase in left atria1 pressure as a result of 
impaired diastolic filling at high heart rates (7-9). To test the 
assumption that exercise capacity is limited by left-sided 
filling pressures, we measured pulmonary capillary wedge 
pressure and cardiac output on exercise and related them to 
objective assessment of exercise capacity in patients with 
hypertrophic cardiomyopathy. 
Methods 
Study patients. Twenty-six consecutive patients with hy- 
pertrophic cardiomyopathy were considered for entry to the 
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study. Three were excluded for the following reasons: 
pulmonary disease in one, severe mitral regurgitation in one 
and inability to exercise due to painful liver congestion in 
another. The remaining 23 patients in whom exercise was 
limited only by dyspnea or fatigue were studied. Thirteen 
were in New York Heart Association functional class I, 8 in 
class II and 2 in class III. They were aged 15 to 70 (median 
30) years. Twenty-two patients had sinus rhythm and one 
had well controlled atria1 fibrillation. All underwent conven- 
tional two-dimensional echocardiographic (10,l l), Doppler 
(12), radionuclide (13) and ambulatory electrocardiographic 
(14) assessment (Table 1). The clinical diagnosis of hyper- 
trophic cardiomyopathy was confirmed by the echocardio- 
graphic demonstration of unexplained left ventricular hyper- 
trophy (15). Patients with sustained hypertension (>150/90 
mm Hg) were excluded. Twenty-three age- and gender- 
matched normal volunteers also entered the study and 
underwent exercise testing with respiratory gas analysis, but 
not hemodynamic assessment. 
Exercise testing. Before the study all subjects underwent 
at least three practice exercise tests. When maximal oxygen 
consumption in two consecutive exercise tests differed by 
0735.1097/89/$3.50 
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Table 1. Clinical, Echocardiographic, Radionuclide and Electrocardiographic Criteria in 23 Patients With Hypertrophic Cardiomyopathy 
Age Max 
Patient (Yr) & NYHA WT LA LVEDD PG EF PER PFR 
No. Gender Class Rx (mm) (mm) (mm) Pattern RVH (mm Hn) (c/o) (EDVK’) (EDV.s-‘) SVT VT 
1 45M 
2 25F 
3 41M 
4 23F 
5 70F 
6 25F 
1 35M 
8 30M 
9 42M 
10 30F 
II 26M 
12 42M 
13 51M 
14 23F 
I5 15F 
16 25M 
17 22M 
18* 44M 
19 21M 
20 41M 
21 49F 
22 54F 
23 29M 
I 
III 
II 
I 
II 
II 
I 
I 
II 
I 
1 
I 
I 
II 
II 
II 
I 
III 
I 
II 
I 
I 
I 
CCB 23 
None 26 
None 22 
None 15 
CCB I5 
None 21 
CCB.BB 27 
None 20 
None 23 
None 22 
A 19 
None 20 
None 23 
None 21 
None 30 
None 29 
None 20 
A 24 
None 23 
None 21 
A,BB 20 
None 19 
None 27 
35 36 ASH 
49 37 ASH 
30 48 ASH 
28 36 ASH 
40 40 Symm 
40 40 ASH 
39 45 ASH 
31 47 ASH 
60 41 ASH 
42 36 ASH 
40 42 Distal 
43 45 ASH 
53 50 ASH 
33 41 Distal 
40 48 ASH 
44 43 ASH 
32 41 ASH 
57 55 ASH 
38 39 ASH 
35 54 ASH 
35 39 ASH 
31 50 Distal 
45 41 ASH 
No 64 80 4.49 
Yes 42 79 3.50 
Yes 42 81 3.93 
No - 67 3.93 
No 30 85 5.13 
No <20 65 4.56 
No <20 81 3.70 
No <20 19 3.84 
No 64 - - 
No <20 92 4.19 
No <20 65 4.93 
No 100 71 3.32 
Yes <20 65 4.61 
No <20 85 5.64 
No <20 74 4.45 
Yes <20 68 3.50 
No <20 78 3.83 
No <20 44 2.45 
No - 84 3.60 
Yes <20 - - 
No 77 77 2.85 
Yes <20 - - 
No 55 - - 
3.42 No 
3.03 Yes 
2.81 Yes 
4.91 No 
6.55 Yes 
4.29 No 
2.55 No 
2.65 No 
- No 
5.13 Yes 
2.07 No 
2.38 Yes 
2.33 No 
4.62 No 
3.35 No 
4.70 Yes 
2.46 No 
1.89 Yes 
2.76 No 
- No 
2.21 No 
- No 
- No 
Yes 
No 
Yes 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
Yes 
No 
No 
No 
No 
No 
*Patient with atrial fibrillation. A = amiodarone: ASH = asymmetric septal hypertrophy; BB = beta-blocker: CCB = calcium channel blocker: EDV = 
end-diastolic volume; EF = ejection fraction: F = female: LA = left atrium; LVEDD = left ventricular end-diastolic dimension; M = male: Max WT = maximal 
wall thickness; NYHA = New York Heart Association classification: PER = peak ejection rate; PFR = peak filling rate; PG = calculated Doppler pressure 
gradient (12): RVH = right ventricular hypertrophy: Rx = treatment: SVT = supraventricular tachycardia; Symm = symmetric; VT = ventricular tachycardia. 
<5%, the subject was considered to be practiced in the 
technique. 
On the day of the study, patients arrived having fasted 
and taken their usual medications. A Swan-Ganz catheter 
was inserted into a subclavian vein under local anesthesia 
and advanced into the pulmonary artery. After 1 h of rest 
patients underwent symptom-limited treadmill exercise ac- 
cording to a modified Bruce protocol with simultaneous 
respiratory gas analysis performed with use of an Airspec 
200MGA mass spectrometer linked to a BBC microcomputer 
with an analog to digital converter by an established tech- 
nique (16). Sampling of mixed expired gases was performed 
every second and data were expressed as 10 s means. A 
printout of minute ventilation, oxygen consumption, carbon 
dioxide production and respiratory quotient was obtained. 
Maximal oxygen consumption was defined as the mean of 
the highest two values of oxygen consumption obtained 
during exercise. Anaerobic threshold was determined by one 
of the conventional methods (17). In brief, the mean value 
and 2 SD for all of the 10 s respiratory quotient values 30% 
of maximal oxygen consumption were calculated. At higher 
work loads carbon dioxide production increases dispropor- 
tionately relative to oxygen consumption with a consequent 
rise in respiratory quotient. When two of three consecutive 
respiratory quotient measurements lay outside 2 SD from the 
mean value obtained at lower work loads, the oxygen 
consumption at the first of these measurements was defined 
as the anaerobic threshold. 
Pulmonary artery systolic and pulmonary capillary 
wedge pressures and cardiac output were measured with the 
patient supine and erect before exercise and erect during 
each minute of exercise. Pressures were measured by Gould- 
Statham transducers referenced to atmosphere at mid-chest 
level, and recorded on a Mingograf 7 multichannel recorder. 
Cardiac output was determined by the Fick method as: 
Cardiac output (litersimin) = 
maximal oxygen consumption (mlimin) X 10 
hemoglobin (gidl) x 1.34 x arteriovenous oxygen difference ’ 
Statistical methods. Data are expressed as mean values 2 
1 SD unless otherwise stated. Statistical analysis was per- 
formed with Student’s t test for paired data and with 
correlation coefficient and linear regression when appropri- 
ate. 
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Table 2. Exercise Capacity and Hemodynamics in 23 Patients With Hypertrophic Cardiomyopathy 
PCWP (mm Hg) Cl (litersimin per m’) 
Patient VO, max AT .At vo, of I5 ;\t Peak 
No. (ml/kg per mini (ml/kg per min) At Rest (ml/kg per min) Peak 41 Rest Ex 
I 24.39 17.05 5 I! 48 7.07 5.60 
2 ‘1 __.. 17 18.43 I! 16 28 3.13 7.14 
3 21.53 17.70 0 5 I8 2.5x 8.26 
4 36.32 34.20 0 22 22 2.26 8.06 
5 2 I .36 20.81 7 I! I7 2.00 9.08 
6 24.80 15.81 0 9 12 3.00 10.16 
7 20.69 13.79 0 I2 IX 3.98 7.0 
8 34.75 22.39 0 I3 32 2.35 X.78 
9 21.68 16.08 0 IX 25 I.16 5.41 
IO 7i _. ._ 76 15.71 0 25 37 2.3 6.92 
II 42.00 24.00 6 25 30 I.77 9.95 
I2 3u.00 24.8 I7 37 35 3.41 7.88 
I3 2X.83 25.2 IO 16 28 I .95 9.5 
I4 23.54 20.55 6 10 20 2.05 4.3 
I5 30.77 NA 2 N.4 7 2.33 7.94 
I6 22.05 20.07 I5 35 40 I.7 5.28 
I7 35.x4 25.70 2 I2 I7 1.93 II.42 
18 16.49 18.04 I5 27 27 2.06 6.37 
19 41.30 31.20 0 0 I2 _.. 1 <i 13.0 
20 T1 ‘._._ ‘0 16.60 6 I7 20 2.66 8.9 
21 21.30 14.90 0 22 40 2.62 7.55 
22 3X.80 35.30 2 2 8 2.36 8.44 
23 36.80 23.70 8 7 I7 7.44 9.33 
Mean SD 28.09 ? 7.53 21.46 ? 6.1 4.91 2 5.58 16.77 ? 9.58 24.26 ? 10.88 2.38 + 0.6 8.1 ? 2.04 
AT = anaerobic threshold; CI = cardiac index: Ex = exercise: NA = not available: PCWP = mean pulmonary capillary wedge pressure: VOz max = maximal 
oxygen consumption. 
Results 
Maximal oxygen consumption and anaerobic threshold. 
Exercise was terminated by breathlessness rather than fa- 
tigue in all patients, and was completed without complica- 
tion. Maximal oxygen consumption and anaerobic threshold 
for the patients were 28.1 -+ 7.50 and 21.5 ? 6.1 ml/kg per 
min, respectively. Maximal oxygen consumption and anaer- 
obic threshold in the age- and sex-matched normal subjects 
were 39 to 68 (mean 47) and 27 to 58 (mean 411 ml/kg per min, 
respectively (Table 2). 
Correlation with pulmonary capillary wedge pressure and 
cardiac index. Mean pulmonary capillary wedge pressure of 
patients in the supine position and at rest was 15 + 5 mm Hg. 
Erect mean pulmonary capillary wedge pressure increased 
from 5 2 5 mm Hg at rest to 24 ? 11 at peak exercise (p < 
0.001) and cardiac index increased from 2.4 + 0.6 litersimin 
per m2 at rest to 8.1 -f 2.1 at peak exercise (p < 0.001) (Table 
2). 
Maximal oxygen consumption and anaerobic threshold 
were related to the peak cardiac index and the increase in 
cardiac index on exercise but not to cardiac index at rest. 
They were not related to either rest or peak pulmonary 
capillary wedge pressure, the change in pulmonary capillary 
wedge pressure on exercise, or the pulmonary capillary 
wedge pressure at the time when oxygen consumption was 
I5 ml/kg per min (Table 3. Fig. 1 and 2). 
Other correlations. Exercise capacity was not related to 
conventional radionuclide indexes of systolic or diastolic 
function or to echocardiographic left atria1 size, left ventric- 
ular end-diastolic dimension or maximal wall thickness. 
Table 3. Relation of Exercise Capacity to Hemodynamic 
Variables in 23 Patients 
VOzmax AT 
r P r P 
CI 
At rest -0.113 NS -0.157 NS 
Peak 0.650 <O.OOl 0.459 =0.03 
Change on exercise 0.6771 10.001 0.509 =0.016 
PCWP 
At rest -0.212 NS 0.008 NS 
Peak -0.297 NS -0.378 NS 
Change on exercise -0.197 NS -0.378 NS 
At VO, of 15 ml/kg -0.301 NS -0.232 NS 
per min 
Abbreviations as in Table 2 
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Figure 1. Relation of maximal oxygen consumption (VO, max [ml/kg 
per min]) and the change in pulmonary capillary wedge pressure 
(PCWP [mm Hg]) from rest to peak exercise. 
Figure 2. Relation of maximal oxygen consumption (VO, max [ml/kg 
per min]) and the change in cardiac index (CI [literslmin per m’]) 
from rest to peak exercise. 
Discussion 
Dyspnea in hypertrophic cardiomyopathy. Breathlessness 
was the limiting symptom in all 23 patients studied. Exercise 
capacity as assessed by maximal oxygen consumption was 
moderately impaired in all but 2 patients, even though 13 
were in functional class I and claimed normal exercise 
tolerance. This finding serves to emphasize the limitation of 
specific activity scales in the assessment of exercise capac- 
ity, particularly in patients with long-standing disability. It 
has been stated that the most common symptom in hyper- 
trophic cardiomyopathy is shortness of breath resulting from 
an increased left atria1 pressure caused by the stiff left 
ventricle and its high diastolic pressure (7-9). Observation of 
a patient (Table 2, Patient 3) with marked exercise dyspnea 
associated with normal rest and peak exercise pulmonary 
capillary wedge pressures led us to question this hypothesis. 
Role of cardiac output and left atrial pressure during 
exercise. This study demonstrates that exercise capacity in 
hypertrophic cardiomyopathy is related to cardiac output, as 
it is in normal subjects and patients with heart failure (17,18). 
It also confirms previous reports (7-9) of an abnormal 
increase in left atria1 pressure on exercise in hypertrophic 
cardiomyopathy. If the magnitude of the rise in left atria1 
pressure was a major determinant of exercise capacity, then 
one would expect a statistical relation to exist between the 
two. In this group of 23 patients with hypertrophic cardio- 
myopathy, exercise capacity was not related to pulmonary 
capillary wedge pressure measured at rest, at peak exercise 
or at a submaximal oxygen consumption value of 15 ml/kg 
per min, or to the increase in pulmonary capillary wedge 
pressure from rest to peak exercise. We therefore conclude 
that, in the patients studied, left atria1 pressure was not a 
major determinant of exercise capacity. 
Do these findings apply to other patients with hyper- 
trophic cardiomyopathy? In this regard, the exercise capac- 
ity and pulmonary capillary wedge pressure at rest of the 23 
patients are representative of larger consecutive series 
(6,19). In patients with severe mitral regurgitation, the 
increase in left atria1 pressure would be expected to be of 
greater importance in determining exercise capacity. Al- 
though mild to moderate mitral regurgitation is common in 
hypertrophic cardiomyopathy (20,21), severe mitral regurgi- 
tation is rare (21,22) and one patient with this condition was 
excluded at the time of initial screening. Thus, our findings 
are probably applicable to patients with hypertrophic cardio- 
myopathy in general, with the exception of patients with 
significant mitral regurgitation. Although this finding is con- 
trary to traditional teaching, it is perhaps not surprising 
because in chronic heart failure there is similarly no relation 
between exercise capacity and left atria1 pressure (17,23), 
and other factors have been shown to be important. 
Metabolic changes during exercise. Studies in patients 
with chronic heart failure have demonstrated that the symp- 
tom that terminates exercise (that is, breathlessness or 
fatigue) depends on the type of exercise performed, and it 
has been suggested (17) that metabolic changes during exer- 
cise may contribute to the hyperventilatory response. Ultra- 
structural and histochemical changes have been demon- 
strated in limb skeletal muscle in patients with chronic heart 
failure (24). It has been proposed (25) that these changes may 
be due to impaired oxygen delivery to skeletal muscle. 
Although therapeutic interventions in patients with chronic 
heart failure may result in rapid improvement in hemody- 
namic variables, there is a considerable delay before an 
objective increase in exercise capacity can be detected 
(26,27). This delay has led to the suggestion (28) that stiffness 
of small blood vessels, perhaps as a result of edema of the 
vessel wall, may contribute to inadequate oxygen delivery to 
skeletal muscle, which may take time to resolve, thus 
explaining the delayed improvement in exercise capacity. In 
patients with hypertrophic cardiomyopathy, treatment with 
verapamil has been shown to be associated with prolonga- 
tion of treadmill exercise duration at 5 days (29), and edema 
of the blood vessel wall is therefore unlikely to be an 
JACC Vol. 13. No. 7 
June 1989: 1521-h 
FRENNEAUX ET AL. 152.5 
EXERCISE IN HYPERTROPHIC CARDIOMYOPATHY 
important factor. The relation of exercise capacity and 
cardiac index is, however, consistent with the concept that 
skeletal muscle blood flow may be a limiting factor. 
Respiratory muscle fatigue. Respiratory muscle fatigue 
may contribute to the perception of breathlessness in normal 
subjects (30) and in patients with obstructive airways disease 
(3 1). It is possible that inadequate oxygen delivery to respi- 
ratory muscle may occur in patients with heart disease and 
result in premature respiratory muscle fatigue. Abnormal 
respiratory muscle function has been demonstrated in pa- 
tients with mitral stenosis, but it is not clear whether this 
relates to the loss of respiratory muscle bulk as a conse- 
quence of cachexia (32). The possible role of premature 
respiratory muscle fatigue in patients with hypertrophic 
cardiomyopathy has not been investigated. 
Subjective factors. Breathlessness is a subjective sensa- 
tion, and perception of it may differ from patient to patient in 
much the same way as pain threshold varies. Thus, although 
each subject continues to exercise to a perceived maximal 
tolerance of dyspnea, the latter may vary from patient to 
patient. Administration of dihydrocodeine to patients with 
chronic obstructive airways disease has been shown to 
relieve the sensation of breathlessness and increase exercise 
tolerance (33). Thus, central modulation may play an impor- 
tant role in determining the sensation of breathlessness and, 
therefore, exercise capacity. This area has not been explored 
in patients with heart disease. 
Conclusions. Contrary to the commonly accepted belief. 
the increase in left atrial pressure does not appear to be a 
major determinant of exercise capacity in hypertrophic 
cardiomyopathy. The role of other factors, including those 
described in this study, requires further investigation. 
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